Yunlong Zhang, Changchun Li, Xiaobin Deng, Fumihiko Urabe, Mauricio Burotto, Sebastiano Buti, Giulia Claire Giudice, Zhenzhen Zhao, Chao Yang, Jian Sun, Yifei Du, Shan Wang
BACKGROUND: Microphthalmia-associated transcription factor/transcription factor E (MiTF/TFE) translocation renal cell carcinoma (RCC) is a rare type of non-clear cell RCC (nccRCC), which is more common in females. Currently, there is no standardized treatment for advanced metastatic microphthalmia translocation RCC (MiT-RCC). The main treatment modalities include surgery, chemotherapy, immunotherapy, anti-vascular endothelial growth factor or vascular endothelial growth factor receptor (VEGFR) inhibitors, mammalian target of rapamycin (mTOR) inhibitors, and targeted therapy against the mesenchymal-epithelial transition (MET) factor signaling pathway...
March 27, 2024: Translational Pediatrics